Proposing Vascepa (Icosapent Ethyl) as Supplemental Treatment for Persistent Post-Viral Symptoms of COVID-19: A Case Series
July 2022
Studysummary This case series observed that patients with persistent post-COVID-19 symptoms reported considerable improvement after using icosapent ethyl, suggesting potential therapeutic success warranting further research.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on doi.org →